Movement Alert｜PegBio Falls 5.14% in Regular Trading, Pullback Continues Amid Lock-Up Expiry Concerns Following Multi-Day Rally

Market Focus

05/21

On May 21, PegBio Co Ltd (02565.HK) fell 5.14% in regular trading, trading at HK$14.38/share with trading volume of HK$29.44 million, extending a multi-day pullback after its explosive rally earlier in the week.

The decline follows concerns over a share lock-up expiry period. The stock had surged over 100% on May 18 after the company announced a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market. Under the agreement, Tengrui will pay approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The stock continued climbing on May 19 and May 20 before reversing course.

The current retreat contrasts with the broader Biotechnology sector, where peers including AKESO (+7.13%), REMEGEN (+5.13%), INNOVENT BIO (+3.97%), BEIGENE (+3.04%), and 3SBIO (+2.44%) posted gains during the session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1162345639"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162345639\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162345639?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 10:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162345639","market":"us","top_or_hot":-1,"title":"Movement Alert｜PegBio Falls 5.14% in Regular Trading, Pullback Continues Amid Lock-Up Expiry Concerns Following Multi-Day Rally","media":"Market Focus","content":"<p><p>On May 21, PegBio Co Ltd (02565.HK) fell 5.14% in regular trading, trading at HK$14.38/share with trading volume of HK$29.44 million, extending a multi-day pullback after its explosive rally earlier in the week.</p><p>The decline follows concerns over a share lock-up expiry period. The stock had surged over 100% on May 18 after the company announced a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market. Under the agreement, Tengrui will pay approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The stock continued climbing on May 19 and May 20 before reversing course.</p><p>The current retreat contrasts with the broader Biotechnology sector, where peers including AKESO (+7.13%), REMEGEN (+5.13%), INNOVENT BIO (+3.97%), BEIGENE (+3.04%), and 3SBIO (+2.44%) posted gains during the session.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PegBio Falls 5.14% in Regular Trading, Pullback Continues Amid Lock-Up Expiry Concerns Following Multi-Day Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PegBio Falls 5.14% in Regular Trading, Pullback Continues Amid Lock-Up Expiry Concerns Following Multi-Day Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-21 10:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 21, PegBio Co Ltd (02565.HK) fell 5.14% in regular trading, trading at HK$14.38/share with trading volume of HK$29.44 million, extending a multi-day pullback after its explosive rally earlier in the week.</p><p>The decline follows concerns over a share lock-up expiry period. The stock had surged over 100% on May 18 after the company announced a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market. Under the agreement, Tengrui will pay approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The stock continued climbing on May 19 and May 20 before reversing course.</p><p>The current retreat contrasts with the broader Biotechnology sector, where peers including AKESO (+7.13%), REMEGEN (+5.13%), INNOVENT BIO (+3.97%), BEIGENE (+3.04%), and 3SBIO (+2.44%) posted gains during the session.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1162345639","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162345639","pubTimestamp":1779329149,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 21, PegBio Co Ltd (02565.HK) fell 5.14% in regular trading, trading at HK$14.38/share with trading volume of HK$29.44 million, extending a multi-day pullback after its explosive rally earlier...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"走势警报|PegBio常规交易下跌5.14%，在多日上涨后，禁售期到期担忧持续回调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"On May 21, PegBio Co Ltd (02565.HK) fell 5.14% in regular trading, trading at HK$14.38/share with trading volume of HK$29.44 million, extending a multi-day pullback after its explosive rally earlier in the week.The decline follows concerns over a share lock-up expiry period. The stock had surged over 100% on May 18 after the company announced a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market. Under the agreement, Tengrui will pay approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The stock continued climbing on May 19 and May 20 before reversing course.The current retreat contrasts with the broader Biotechnology sector, where peers including AKESO (+7.13%), REMEGEN (+5.13%), INNOVENT BIO (+3.97%), BEIGENE (+3.04%), and 3SBIO (+2.44%) posted gains during the session.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}